Alphabetical listing of all products

  • 5 mg - 85 EUR
  • 25 mg - 340 EUR
  • 100 mg - 1020 EUR


Linsitinib has been developed as a small-molecule inhibitor of IGF-1R and IR kinases, with IC50 values of 35 nM and 75 nM, respectively. Linsitinib potently and selectively inhibits autophosphorylation of both human IGF-1R and IR in cells, displays in vitro antiproliferative effects in a variety of tumor cell lines and robust in vivo anti-tumor efficacy in a xenograft model. It undergoes clinical trials as a drug against several cancer types including adrenocortical, lung and ovarian carcinomas.

catalogue number: L168
synonyms: OSI-906, OSI 906AA
CAS: 867160-71-2
MW: 421.51 g/mol

Future Med Chem. 2009 Sep;1(6):1153-71. PMID: 21425998
Mol Cancer Ther. 2010 Oct;9(10):2652-64. PMID: 20924128
Cancer Treat Rev. 2012 Jun;38(4):292-302. PMID: 21907495